title: Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonresponsive to drug therapy alone.
abstract: In this report we present a 28-year-old male patient with systemic lupus erythematosus (SLE) that was treated with immunoadsorption apheresis (IA) and cyclophosphamide for lupus nephritis (proliferative glomerulonephritis, class IV-B) after proving nonresponsive to drug therapy alone. Before starting the therapeutic cycle with IA, the patient was administered prednisone 25 mg/d, hydroxychloroquine 200mg twice/d, ACE inhibitors 5 mg/d, aspirin 100 mg/d, furosemide 50 mg/d, and intravenous (IV) albumin (20%) 50 mL. Deteriorating clinical conditions necessitated a renal biopsy, and thereafter an increase in medication. The patient was given a bolus of IV cyclophosphamide 1 g/d for 1 day and IV methylprednisone 500 mg/d for 3 days. This was not followed by any improvement and the renal functions worsened. Thus, 3 weeks after the more aggressive pharmacologic treatment with cyclophosphamide, which had been prescribed to improve renal function, and given the young age of the patient, the decision was made to administer IA (Selesorb). IA selectively removes IgG and IgM immune complexes from the plasma, thereby reducing the complications induced by the pathogenic autoimmune reaction. The treatment was administrated twice a week for the first 15 days, once a week for a further 5 weeks, and biweekly in the last month with a bolus of cyclophosphamide (average 250-100 mg) after each session. After twelve sessions of IA over 3 months, renal function was completely restored and the patient discharged. Although it is not proven, the concomitant use of cyclophosphamide could presumably improve the final clinical outcome.
authors.affiliation: Applied Clinical and Medical Therapy Department, University of Rome La Sapienza, Policlinico Umberto I, Rome, Italy. plasmaferesi@tin.it
authors.forename: Claudia
authors.initials: C
authors.lastname: Stefanutti
authors.forename: Antonio
authors.initials: A
authors.lastname: Vivenzio
authors.forename: Serafina
authors.initials: S
authors.lastname: Di Giacomo
authors.forename: Maura
authors.initials: M
authors.lastname: Mareri
authors.forename: Fulvia
authors.initials: F
authors.lastname: Ceccarelli
authors.forename: Guido
authors.initials: G
authors.lastname: Valesini
mesh_terms: D000328:Adult; D001781:Blood Component Removal; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D016264:Dextran Sulfate / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007163:Immunosorbent Techniques; D007275:Injections, Intravenous; D007558:Italy / Q000453:epidemiology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D003520:Cyclophosphamide; D016264:Dextran Sulfate